Ad hoc: GPC Biotech AG: GPC Biotech Reports that Celgene to Terminate Co-Development andLicense Agreement for Satraplatin

GPC Biotech AG / Contract / GPC Biotech Reports that Celgene to 
Terminate Co-Development and
License Agreement for Satraplatin
 
Ad hoc announcement according to §15 WpHG processed and transmitted 
by Hugin ASA. The issuer is solely responsible for the content of 
this announcement.     
 
----------------------------------------------------------------------
--------------
 
Martinsried/Munich (Germany) and  Princeton, N.J., August  6, 2008  -
GPC Biotech AG  (Frankfurt Stock Exchange:  GPC, NASDAQ: GPCB)  today
reported  that  the   Company  has  received   notice  from   Celgene
Corporation of  its  decision  to terminate  its  co-development  and
license agreement with GPC Biotech for satraplatin in Europe, Turkey,
the Middle  East, Australia  and New  Zealand.  All  rights to  these
territories will be returned  to GPC Biotech.   The Company plans  to
decide in the near future the next steps regarding the development of
satraplatin.
 
End of Ad Hoc Announcement
 
This ad hoc announcement  contains forward-looking statements,  which
express the current beliefs and expectations of the management of GPC
Biotech. Such statements  are based on  current expectations and  are
subject to  risks and  uncertainties, many  of which  are beyond  our
control, that could cause future results, performance or achievements
to differ significantly from the results, performance or achievements
expressed or  implied  by  such  forward-looking  statements.  Actual
results could differ materially depending on a number of factors, and
we  caution   investors  not   to  place   undue  reliance   on   the
forward-looking statements contained in this ad hoc announcement.  We
direct you to GPC Biotech's Annual Report on Form 20-F for the fiscal
year ended December 31,  2007 and other reports  filed with the  U.S.
Securities and  Exchange Commission  for  additional details  on  the
important factors that may affect the future results, performance and
achievements of GPC Biotech. Forward-looking statements speak only as
of the date  on which  they are made  and GPC  Biotech undertakes  no
obligation to update  these forward-looking statements,  even if  new
information becomes available in the future.
 
For further information, please contact:
 
GPC Biotech AG
Investor Relations & Corporate Communications
Phone: +49 (0)89 8565-2693
ir@gpc-biotech.com
 
In the U.S.: Laurie Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 609-524-5884
usinvestors@gpc-biotech.com
 
Additional media contacts for Europe:
MC Services AG
Phone:  +49 (0) 89 210 228 0
 
Raimund Gabriel
raimund.gabriel@mc-services.eu
 
Hilda Juhasz
hilda.juhasz@mc-services.eu
 
Additional investor contact for Europe:
Trout International LLC
Mike Booth, Senior Vice President
Phone: +44 207 936 9326
mbooth@troutgroup.com
 
--- End of Message  ---
 
GPC Biotech AG
Fraunhoferstr. 20 Martinsried 
 
WKN: 585150; ISIN: 
DE0005851505; Index: CDAX, MIDCAP, Prime All Share, TecDAX, HDAX, 
TECH All Share;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in 
Börse Berlin, 
Freiverkehr in Bayerische Börse München, Freiverkehr in Börse 
Düsseldorf, 
Freiverkehr in Börse Stuttgart, Freiverkehr in Hanseatische 
Wertpapierbörse zu Hamburg, 
Geregelter Markt in Frankfurter Wertpapierbörse;